Przedstawiamy wybór publikacji naukowych związanych z immunoterapią IOZK. Możesz użyć filtrów, aby dokonać wyboru według typów nowotworów i metod lub wprowadzić wyszukiwane hasła.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002019-11-01 / Am J Cancer Res 2019;9(11):2456-2468https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2019-11-01 / Am J Cancer Res 2019;9(11):2456-24682019-11-01 00:00:002019-11-01 00:00:00Dendritic cell immunotherapy induces anti-tumor effect in a transgenic mouse model of pancreatic ductal adenocarcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002019-11-01 / Int J Cancer 2020 01;146(2):531-541https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2019-11-01 / Int J Cancer 2020 01;146(2):531-5412019-11-01 00:00:002020-12-14 17:16:09Evaluation of Newcastle disease virus mediated dendritic cell activation and cross-priming tumor-specific immune responses ex vivo
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002019-10-29 / Future Sci OA 2019 Oct;5(10):FSO435https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2019-10-29 / Future Sci OA 2019 Oct;5(10):FSO4352019-10-29 00:00:002019-10-29 00:00:00Substantial remission of prostate adenocarcinoma with dendritic cell therapy APCEDEN in combination with chemotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002019-10-11 / Front Pharmacol 2019;10:1152https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2019-10-11 / Front Pharmacol 2019;10:11522019-10-11 00:00:002019-10-11 00:00:00Immunotherapy Based on Dendritic Cell-Targeted/-Derived Extracellular Vesicles-A Novel Strategy for Enhancement of the Anti-tumor Immune Response
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002019-10-11 / Biomedicines 2019 Oct;7(4)https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2019-10-11 / Biomedicines 2019 Oct;7(4)2019-10-11 00:00:002021-05-19 12:40:37Survival Comparison between Melanoma Patients Treated with Patient-Specific Dendritic Cell Vaccines and Other Immunotherapies Based on Extent of Disease at the Time of Treatment
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002019-10-08 / Int. J. Cancer 2020 05;146(10):2822-2828https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2019-10-08 / Int. J. Cancer 2020 05;146(10):2822-28282019-10-08 00:00:002019-10-08 00:00:00A chirality-dependent action of vitamin C in suppressing Kirsten rat sarcoma mutant tumor growth by the oxidative combination: Rationale for cancer therapeutics
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002019-10-03 / Cancers (Basel) 2019 Oct;11(10)https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2019-10-03 / Cancers (Basel) 2019 Oct;11(10)2019-10-03 00:00:002019-10-03 00:00:00Immune Dysfunctions and Immunotherapy in Colorectal Cancer: The Role of Dendritic Cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002019-09-30 / Sci Rep 2019 Sep;9(1):13999https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2019-09-30 / Sci Rep 2019 Sep;9(1):139992019-09-30 00:00:002020-12-14 17:17:18Evaluation of a Recombinant Newcastle Disease Virus Expressing Human IL12 against Human Breast Cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002019-09-27 / Front Mol Biosci 2019;6:90https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2019-09-27 / Front Mol Biosci 2019;6:902019-09-27 00:00:002020-12-14 17:15:172-Deoxyglucose and Newcastle Disease Virus Synergize to Kill Breast Cancer Cells by Inhibition of Glycolysis Pathway Through Glyceraldehyde3-Phosphate Downregulation
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002019-09-11 / Front Oncol 2019;9:884https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2019-09-11 / Front Oncol 2019;9:8842019-09-11 00:00:002019-09-11 00:00:00Past, Current, and Future of Immunotherapies for Prostate Cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002019-09-01 / Jpn. J. Clin. Oncol. 2019 Sep;49(9):832-838https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2019-09-01 / Jpn. J. Clin. Oncol. 2019 Sep;49(9):832-8382019-09-01 00:00:002020-08-26 14:25:47Phase I/II clinical trial of modulated electro-hyperthermia treatment in patients with relapsed, refractory or progressive heavily treated ovarian cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002019-09-01 / J. Neurosurg. 2019 09;131(3):657-666https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2019-09-01 / J. Neurosurg. 2019 09;131(3):657-6662019-09-01 00:00:002019-09-01 00:00:00The current state of immunotherapy for gliomas: an eye toward the future
Dendritic cell immunotherapy induces anti-tumor effect in a transgenic mouse model of pancreatic ductal adenocarcinoma
Evaluation of Newcastle disease virus mediated dendritic cell activation and cross-priming tumor-specific immune responses ex vivo
Substantial remission of prostate adenocarcinoma with dendritic cell therapy APCEDEN in combination with chemotherapy
Vitamin C protects carboplatin-exposed oocytes from meiotic failure
Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine
Extracellular Vesicles in Cancer Immune Microenvironment and Cancer Immunotherapy
Dendritic cells in pancreatic cancer immunotherapy: Vaccines and combination immunotherapies
Immunotherapy Based on Dendritic Cell-Targeted/-Derived Extracellular Vesicles-A Novel Strategy for Enhancement of the Anti-tumor Immune Response
Survival Comparison between Melanoma Patients Treated with Patient-Specific Dendritic Cell Vaccines and Other Immunotherapies Based on Extent of Disease at the Time of Treatment
Dendritic Cell Vaccination in Metastatic Melanoma Turns „Non-T Cell Inflamed“ Into „T-Cell Inflamed“ Tumors
A chirality-dependent action of vitamin C in suppressing Kirsten rat sarcoma mutant tumor growth by the oxidative combination: Rationale for cancer therapeutics
Curcumin and Cancer
Immune Dysfunctions and Immunotherapy in Colorectal Cancer: The Role of Dendritic Cells
Evaluation of a Recombinant Newcastle Disease Virus Expressing Human IL12 against Human Breast Cancer
2-Deoxyglucose and Newcastle Disease Virus Synergize to Kill Breast Cancer Cells by Inhibition of Glycolysis Pathway Through Glyceraldehyde3-Phosphate Downregulation
Blockade of PD-L1 Enhances Cancer Immunotherapy by Regulating Dendritic Cell Maturation and Macrophage Polarization
Dendritic Cell-Based and Other Vaccination Strategies for Pediatric Cancer
Past, Current, and Future of Immunotherapies for Prostate Cancer
Phase I/II clinical trial of modulated electro-hyperthermia treatment in patients with relapsed, refractory or progressive heavily treated ovarian cancer
The current state of immunotherapy for gliomas: an eye toward the future